VIDEO: Miebo shows efficacy for mild, moderate dry eye treatment
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ARVO meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis investigating Miebo for the treatment of dry eye disease at different levels of severity.
Data for the analysis were collected from the MOJAVE and GOBI trials and included patients treated with Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) who had mild and moderate scores for total corneal fluorescein staining, meibomian gland dysfunction and Schirmer’s test at baseline.
“The post hoc analyses of pulled data from these two phase 3 randomized controlled trials indicates that [perfluorohexyloctane] is efficacious in the treatment of signs and symptoms of dry eye disease in patients with either mild or moderate disease,” he said. “This is useful information for the prescribing eye care provider.”
Collapse
Sheppard JD, et al. Efficacy of perfluorohexyloctane ophthalmic solution in patients with dry eye disease stratified by baseline severity. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about
Click Here to Manage Email Alerts